Dentsply Sirona: 3 Key Takeaways for Long-Term Investors
XRAY Q3 2026 deep dive: revenue shortfall and guidance cut amid dental market headwinds
Dentsply Sirona (XRAY) stock trades down, here is why
DENTSPLY SIRONA (XRAY) Cuts 2026 Guidance, Is The 24% Undervalued View Still Credible?
Dentsply Sirona Stock Looks Tougher After Revenue Miss And Lower Guidance
DENTSPLY SIRONA Inc. 2026 Q3 - Results - Earnings Call Presentation
DENTSPLY SIRONA Inc. (XRAY) Q3 2026 Earnings Call Transcript
DENTSPLY SIRONA Q3 Earnings Call Highlights
DENTSPLY (XRAY) Q3 2026 Earnings Call Transcript
DENTSPLY SIRONA Inc. Q3 2026 Earnings Call Summary
XRAY Stock Declines as Q3 Earnings & Sales Miss Estimates, Outlook Cut
Dentsply (XRAY) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Dentsply Sirona (NASDAQ:XRAY) misses Q3 2026 revenue estimates, stock drops 14.4%
Dentsply Sirona Reports Third Quarter 2026 Results
Dentsply Sirona Q3 2026 Earnings Call Transcript
Dentsply Sirona Lowers FY2026 Adj EPS Guidance from $1.40-$1.50 to $1.20-$1.30 vs $1.55 Est; Narrows FY2026 Sales Guidance from $3.500B-$3.600B to $3.500B vs $3.570B Est
Dentsply Sirona Q3 Adj. EPS $0.29 Misses $0.31 Estimate, Sales $836.000M Miss $862.001M Estimate
DENTSPLY SIRONA (XRAY) Stock May Be Undervalued Following Fiduciary Duty Investigation
XRAYDentsply Sirona (XRAY) Faces Demand Headwinds Despite Ongoing Turnaround Efforts
Barrington Research Maintains Outperform on Dentsply Sirona, Lowers Price Target to $13
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.